The high-affinity binding between methotrexate and GALE substantially exceeds its binding strength with the classical target TYMS, providing a novel theoretical framework for explaining methotrexate’s unique efficacy in atopic dermatitis treatment. The gene discussed is TYMS; the disease is atopic eczema.